Because A375 MEK1 Q56P melanoma cells carry the activating BRAF V600E mutation as well as an activating MEK1 mutation, inhibition of BRAF alone fails to abrogate aberrant proliferation signaling through downstream MEK proteins, while inhibition of MEK alone cannot effectively compensate for the increase in upstream BRAF signaling. This evidence concerns the gene BRAF and melanoma.